Protein kinase inhibitors as a therapeutic modality

Accounts of Chemical Research

Volumn 36, Issue 6, 2003, Pages 462-469

  Levitzki, Alexander ^a  

^a HEBREW UNIVERSITY OF JERUSALEM   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

4 (3 CHLOROANILINO) 6,7 DIMETHOXYQUINAZOLINE; 6,7 DIMETHOXY 2 PHENYLQUINOXALINE; 6,7 DIMETHYL 2 PHENYLQUINOXALINE; AG 1112; AG 1318; AG 957; AGL 2043; BCR ABL PROTEIN; CISPLATIN; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE; ERBSTATIN; ERLOTINIB; GEFITINIB; GENISTEIN; IMATINIB; LAVENDUSTIN A; N (4 BUTYLPHENYL) ALPHA CYANOCAFFEIC ACID AMIDE; N [4 (3 CHLORO 4 FLUOROANILINO) 7 (3 MORPHOLINOPROPOXY) 6 QUINAZOLINYL]ACRYLAMIDE; N BENZYL 2 CYANO 3 (3,4 DIHYDROXYPHENYL)ACRYLAMIDE; PROTEIN KINASE; PROTEIN KINASE INHIBITOR; PROTEIN SERINE THREONINE KINASE; PYRAZOLOPYRIMIDINE DERIVATIVE; PYRIDOPYRIMIDINE; PYRROLOISATINE; QUERCETIN; QUINAZOLINE; QUINOXALINE DERIVATIVE; TYRPHOSTIN; UNCLASSIFIED DRUG; UNINDEXED DRUG;

CELL FUNCTION; CHRONIC MYELOID LEUKEMIA; ENZYME INHIBITION; ENZYME REGULATION; GENE MUTATION; HUMAN; PROTEIN PHOSPHORYLATION; RESTENOSIS; REVIEW; SIGNAL TRANSDUCTION;

ANTINEOPLASTIC AGENTS; DRUG DESIGN; ENZYME INHIBITORS; HUMANS; MOLECULAR MIMICRY; NEOPLASMS; PIPERAZINES; PROTEIN KINASE INHIBITORS; PROTEIN KINASES; PYRIMIDINES; SIGNAL TRANSDUCTION;

EID: 0037665110     PISSN: 00014842     EISSN: None     Source Type: Journal    
DOI: 10.1021/ar0201207     Document Type: Review

References (85)

1. Levitzki, A.; Gilon, C. Tyrphostins as molecular tools and potential antiproliferative drugs. Trends Pharmacol. Sci. 1991, 12, 171-4.
2. Levitzki, A. Signal-transduction therapy. A novel approach to disease management. Eur. J. Biochem. 1994, 226, 1-13.
3. Levitzki, A. Signal transduction interception as a novel approach to disease management. Ann. N.Y. Acad. Sci. 1995, 766, 363-8.
4. Levitzki, A. Tyrphostins - potential antiproliferative agents and novel molecular tools. Biochem. Pharmacol. 1990, 40, 913-8.
5. Levitzki, A. Tyrphostins: tyrosine kinase blockers as novel anti-proliferative agents and dissectors of signal transduction. Faseb J. 1992, 6, 3275-82.
6. Anafi, M.; Gazit A.; Zehavi A.; Ben-Neriah Y.; Levitzki A. Tyrphostin-induced inhibition of p210bcr-abl tyrosine kinase activity induces K562 to differentiate. Blood 1993, 82, 3524-9.
7. Anafi, M.; Gazit A.; Gilon C.; Ben-Neriah Y.; Levitzki A. Selective interactions of transforming and normal abl proteins with ATP, tyrosine-copolymer substrates, and tyrphostins. J. Biol. Chem. 1992, 267, 4518-23.
8. Meydan, N.; Grunberger, T.; Dadi, H.; Shahar, M.; Arpaia, E.; Lapidot, Z.; Leeder, J. S.; Freedman, M.; Cohen, A.; Gazit, A.; Levitzki, A.; Roifman, C. M. Inhibition of acute lymphoblastic leukaemia by a Jak-2 inhibitor. Nature 1996, 379, 645-8.
9. Druker, B. J.; Lydon, N. B. Lessons learned from the development of an abl tyrosine kinase inhibitor for chronic myelogenous leukemia. J. Clin. Invest. 2000, 105, 3-7.
10. Druker; B. J. Perspectives on the development of a molecularly targeted agent. Cancer Cell 2002, 1, 31-36.
11. Catlett-Falcone R.; Landowski T. H.; Oshiro M. M.; Turkson J.; Levitzki A.; Savino R.; Ciliberto G.; Moscinski L.; Fernandez-Luna J. L.; Nunez G.; Dalton W. S.; Jove R. Constitutive activation of Stat3 signaling confers resistance to apoptosis in human U266 myeloma cells. Immunity 1999, 10, 105-15.
12. Burdelya, L., Catlett-Falcone, R.; Levitzki, A.; Cheng, F.; Mora, L. B.; Sotomayor, E.; Coppola, D.; Sun, J.; Sebti, S.; Dalton, W. S.; Jove, R.; Yu, H. Combination therapy with AG-490 and interieukin 12 achieves greater antitumor effects than either agent alone. Mol. Cancer Ther. 2002, 1, 893-9.
13. Tsai, C. M.; Levitzki, A.; Wu, L. H.; Chang, K. T.; Cheng, C. C.; Gazit, A.; Perng, R. P. Enhancement of chemosensitivity by tyrphostin AG825 in high-p185(neu) expressing non-small cell lung cancer cells. Cancer Res. 1996, 56, 1068-74.
14. Levitzki, A.; Gazit, A. Tyrosine kinase inhibition: an approach to drug development. Science 1995, 267, 1782-8.
15. Yaish, P.; Gazit, A.; Gilon, C.; Levitzki, A. Blocking of EGF-dependent cell proliferation by EGF receptor kinase inhibitors. Science 1988, 242, 933-5.
16. Manning, G.; Whyte, D. B.; Martinez, R.; Hunter, T.; Sudasanam, S. The protein kinase complement of the human genome. Science 2002, 298, 1912-1934.
17. Levitzki, A. Protein tyrosine kinase inhibitors as novel therapeutic agents. Pharmacol. Ther. 1999, 82, 231-9.
18. Kovalenko, M.; Gazit, A.; Bohmer, A.; Rorsman, C.; Ronnstrand, L.; Heldin, C. H.; Waltenberger, J.; Bohmer, F. D.; Levitzki, A. Selective platelet-derived growth factor receptor kinase blockers reverse sis-transformation. Cancer Res. 1994, 54, 6106-14.
19. Strawn, L. M.; McMahon, G.; App, H.; Schreck, R.; Kuchler, W. R.; Longhi, M. P.; Hui, T. H.; Tang, C.; Levitzki, A.; Gazit, A.; Chen, I.; Keri, G.; Orfi, L.; Risau, W.; Flamme, I.; Ullrich, A.; Hirth, K. P.; Shawver, L. K. Flk-1 as a target for tumor growth inhibition. Cancer Res. 1996, 56, 3540-5.
20. Bilder G. E.; Krawiec J. A.; McVety K.; Gazit A.; Gilon C.; Lyall R.; Zilberstein A.; Levitzki A.; Perrone M. H.; Schreiber A. B. Tyrphostins inhibit PDGF-induced DNA synthesis and associated early events in smooth muscle cells. Am. J. Physiol. 1991, 260, C721-30.
21. Bryckaert M. C.; Eldor A.; Fontenay M.; Gazit A.; Osherov N.; Gilon C.; Levitzki A.; Tobelem G. Inhibition of platelet-derived growth factor-induced mitogenesis and tyrosine kinase activity in cultured bone marrow fibroblasts by tyrphostins. Exp. Cell Res. 1992, 199, 255-61.
22. Banai S.; Wolf Y.; Golom, G.; Pearle A.; Waltenberger J.; Fishbein I.; Schneider A.; Gazit A.; Perez L.; Huber, R.; Lazarovichi G.; Rabinovich, L.; Levitzki A.; Gertz S. D. PDGF-receptor tyrosine kinase blocker AG1295 selectively attenuates smooth muscle cell growth in vitro and reduces neointimal formation after balloon angioplasty in swine. Circulation 1998, 97, 1960-9.
23. Parrizas, M.; Gazit, A.; Levitzki, A.; Wertheimer, E.; LeRoith, D. Specific inhibition of insulin-like growth factor-1 and insulin receptor tyrosine kinase activity and biological function by tyrphostins. Endocrinology 1997, 138, 1427-33.
24. Gazit, A.; Yaish, P.; Gilon, C.; Levitzki, A. Tyrphostins I: synthesis and biological activity of protein tyrosine kinase inhibitors. J. Med. Chem. 1989, 32, 2344-52.
25. Gazit, A.; Osherov, N.; Posner, I.; Yaish, P., Poradosu, E.; Gilon, C.; Levitzki, A. Tyrphostins. 2. Heterocyclic and alpha-substituted benzylidenemalononitrile tyrphostins as potent inhibitors of EGF receptor and ErbB2/neu tyrosine kinases. J. Med. Chem. 1991, 34, 1896-907.
26. Posner, I.; Levitzki, A. Kinetics of phosphorylation of the SH2-containing domain of phospholipase C gamma 1 by the epidermal growth factor receptor. FEBS Lett. 1994, 353, 155-61.
27. Kovalenko, M.; Ronnstrand, L.; Heldin, C. H.; Loubtchenkov, M.; Gazit, A.; Levitzki, A.; Bohmer, F. D. Phosphorylation site-specific inhibition of platelet-derived growth factor beta-receptor autophosphorylation by the receptor blocking tyrphostin AG1296. Biochemistry 1997, 36, 6260-9.
28. Ward, W. H.; Cook, P. N.; Slater, A. M.; Davies, D. H.; Holdgate, G. A.; Green, L. R. Epidermal growth factor receptor tyrosine kinase. Investigation of catalytic mechanism, structure-based searching and discovery of a potent inhibitor. Biochem. Pharmacol. 1994, 48, 659-66.
29. Osherov, N.; Levitzki, A. Epidermal-growth-factor-dependent activation of the src-family kinases. Eur. J. Biochem. 1994, 225, 1047-53.
30. Osherov, N.; Gazit, A.; Gilon, C.; Levitzki, A. Selective inhibition of the epidermal growth factor and HER2/neu receptors by tyrphostins. J. Biol. Chem. 1993, 268, 11134-42.
31. Woodburn, J. R.; Barker, A. J.; Gibson, K. H.; Ashton, S. E.; Wakeling, A. E.; Curry, B. J.; Scerlett, L.; Henthorn, L. R. Abstract 4251. Proc. 88th Annu. Meet. AACR 1997, 38.
32. Gazit, A.; App, H.; McMahon, G.; Chen, J.; Levitzki, A.; Bohmer, F. D. Tyrphostins. 5. Potent inhibitors of platelet-derived growth factor receptor tyrosine kinase: structure-activity relationships in quinoxalines, quinolines, and indole tyrphostins. J. Med. Chem. 1996, 39, 2170-7.
33. Levitzki, A.; Gazit, A.; Banai, S.; Golomb, G.; Gertz, D. U.S. Patent 6,358,954, 2002.
34. Gazit, A.; Yee K.; Uecker, A.; Bohmer, F. D.; Sjoblom, T.; Ostman, A.; Waltenberger, J.; Golomb, G.; Banai, S.; Heinrich, M. C.; Levitzki, A. Tricyclic Quinoxalines as potent kinase inhbitors of PDGFR kinase Flt-3 and kit. Bioorg. Med. Chem. 2003, 11 (9), 2007-18.
35. Schindler, T.; Sicheri, F.; Pico, A.; Gazit, A.; Levitzki, A.; Kuriyan, J. Crystal structure of Hck in complex with a Src family-selective tyrosine kinase inhibitor. Mol. Cell 1999, 3, 639-48.
36. Schindler, T.; Bornmann, W.; Pellicena, P.; Miller, W. T.; Clarkson, B.; Kuriyan, J. Structural mechanism for STI-571 inhibition of abelson tyrosine kinase. Science 2000, 289, 1938-42.
37. Waltenberger, J.; Uecker, A.; Kroll, J.; Frank, H.; Mayr, U.; Bjorge, J. D.; Fujita, D.; Gazit, A.; Hombach, V.; Levitzki, A.; Bohmer, F. D. A dual inhibitor of platelet-derived growth factor beta-receptor and Src kinase activity potently interferes with motogenic and mitogenic responses to PDGF in vascular smooth muscle cells. A novel candidate for prevention of vascular remodeling. Circ. Res. 1999, 85, 12-22.
38. Carroll M.; Ohno-Jones S.; Tamura S.; Buchdunger E.; Zimmermann J.; Lydon N. B.; Gilliland D. G.; Druker B. J. CGP 57148, a tyrosine kinase inhibitor, inhibits the growth of cells expressing BCR-ABL, TEL-ABL, and TEL-PDGFR fusion proteins. Blood 1997, 90, 4947-52.
39. Levitzki, A. EGF Receptor As A Therapeutic Target. Lung Cancer 2003, in press.
40. Wakeling, A. E.; Guy, S. P.; Woodburn, J. R.; Ashton, S. E.; Curry, B. J.; Barker, A. J.; Gibson, K. H. ZD1839 (Iressa): an orally active inhibitor of epidermal growth factor signaling with potential for cancer therapy. Cancer Res. 2002, 62, 5749-54.
41. Nagane, M.; Levitzki, A.; Gazit, A.; Cavenee, W. K.; Huang, H. J. Drug resistance of human glioblastoma cells conferred by a tumor-specific mutant epidermal growth factor receptor through modulation of Bcl-XL and caspase-3-like proteases. Proc. Natl. Acad. Sci. U.S.A. 1998, 95, 5724-9.
42. Nagane, M.; Narita, Y.; Mishima, K.; Levitzki, A.; Burgess, A. W.; Cavenee, W. K.; Huang, H. J. Human glioblastoma xenografts overexpressing a tumor-specific mutant epidermal growth factor receptor sensitized to cisplatin by the AG1478 tyrosine kinase inhibitor. J. Neurosurg. 2001, 95, 472-9.
43. Keith, B. R.; Allen, P. P.; Aliigood, K. J.; Crosby, R. M.; Lackey, K.; Gilmer, T. M.; Mullin, R. J. Abstract 4308. Proc. 92nd Annu. Meet. AACR 2001, 42, 803.
44. Wissner, A.; Brawner Floyd, M.; Rabindran, S.; Nilakantan, R.; Greenberger, L.; Shen, R.; Wang, Y.; Tsou, H. Syntheses and EGFR and HER-2 kinase inhibitory activities of 4-anilinoquinoline-3-carbonitriles: analogues of three important 4-anilinoquinazolines currently undergoing clinical evaluation as therapeutic antitumor agents. Bioorg. Med. Chem. Lett. 2002, 12, 2893-7.
45. Kaur, G.; Gazit, A.; Levitzki, A.; Stowe, E.; Cooney, D. A.; Sausville, E. A. Tyrphostin induced growth inhibition: correlation with effect on p210bcr-abl autokinase activity in K562 chronic myelogenous leukemia. Anticancer Drugs 1994, 5, 213-22.
46. Carlo-Stella C.; Regazzi E.; Sammarelli G.; Colla S.; Garau D.; Gazit A.; Savoldo B.; Cilloni D.; Tabilio A.; Levitzki A.; Rizzoli V. Effects of the tyrosine kinase inhibitor AG957 and an Anti-Fas receptor antibody on CD34(+) chronic myelogenous leukemia progenitor cells. Blood 1999, 93, 3973-82.
47. Druker, B. J.; Tamura, S.; Buchdunger, E.; Ohno, S.; Segal, G. M.; Fanning, S.; Zimmermann, J.; Lydon, N. B. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat. Med. 1996, 2, 561-6.
48. Benhar, M.; Engelberg, D.; Levitzki, A. ROS, stress-activated kinases and stress signaling in cancer. EMBO Rep. 2002, 3, 420-5.
49. Heinrich, M. C.; Griffith, D. J.; Druker, B. J.; Wait, C. L.; Ott, K. A.; Zigler, A. J. Inhibition of c-kit receptor tyrosine kinase activity by STI571, a selective tyrosine kinase inhibitor. Blood 2000, 96, 925-32.
50. Novogrodsky, A.; Vanichkin, A.; Patya, M.; Gazit, A.; Osherov, N.; Levitzki, A. Prevention of lipopolysaccharide-induced lethal toxicity by tyrosine kinase inhibitors. Science 1994, 264, 1319-22.
51. Vanichkin, A.; Patya, M.; Gazit, A.; Levitzki, A.; Novogrodsky, A. Late administration of a lipophilic tyrosine kinase inhibitor prevents lipopolysaccharide and Escherichia coli-induced lethal toxicity. J. Infect. Dis. 1996, 173, 927-33.
52. Sevransky, J. E.; Shaked, G.; Novogrodsky, A.; Levitzki, A.; Gazit, A.; Hoffman, A.; Elin, R. J.; Quezado, Z. M.; Freeman, B. D.; Eichacker, P. Q.; Danner, R. L.; Banks, S. M.; Bacher, J.; Thomas, M. L., 3rd; Natanson, C. Tyrphostin AG 556 improves survival and reduces multiorgan failure in canine Escherichia coli peritonitis. J. Clin. Invest. 1997, 99, 1966-73.
53. Lopez-Talavera, J. C.; Levitzki, A.; Martinez, M.; Gazit, A.; Esteban, R.; Guardia, J. Tyrosine kinase inhibition ameliorates the hyperdynamic state and decreases nitric oxide production in cirrhotic rats with portal hypertension and ascites. J. Clin. Invest. 1997, 100, 664-70.
54. Blum, G.; Gazit, A.; Levitzki, A. Catechol bioisosteres substrate competitive inhibitors of IGF-1R. Submitted 2003.
55. Blum, G.; Gazit, A.; Levitzki, A. Substrate competitive inhibitors of IGF-1 receptor kinase. Biochemistry 2000, 39, 15705-12.
56. Karni, R.; Levitzki, A. pp60(cSrc) is a caspase-3 substrate and Is essential for the transformed phenotype of A431 cells. Mol. Cell Biol. Res. Commun. 2000, 3, 98-104.
57. Hanke, J. H.; Gardner, J. P.; Dow, R. L.; Changelian, P. S.; Brissette, W. H.; Weringer, E. J.; Pollok, B. A.; Connelly, P. A. Discovery of a novel, potent, and Src family-selective tyrosine kinase inhibitor. Study of Lck- and FynT-dependent T cell activation. J. Biol. Chem. 1996, 271, 695-701.
58. Karni, R.; Jove, R.; Levitzki, A. Inhibition of pp60c-Src reduces Bcl-XL expression and reverses the transformed phenotype of cells overexpressing EGF and HER-2 receptors. Oncogene 1999, 18, 4654-62.
59. Posner, I.; Engel, M.; Gazit, A.; Levitzki, A. Kinetics of inhibition by tyrphostins of the tyrosine kinase activity of the epidermal growth factor receptor and analysis by a new computer program. Mol. Pharmacol. 1994, 45, 673-83.
60. Benhar, M.; I., D.; D., E.; A., L. Enhanced ROS production in oncogenically transformed cells potentiates c-Jun N-terminal kinase and p38 mitogen-activated protein kinase activation and sensitization to genotoxic stress. Mol. Cell Biol. 2001, 21, 6913-26.
61. Dvir, A.; Milner, Y.; Chomsky, O.; Gilon, C.; Gazit, A.; Levitzki, A. The inhibition of EGF-dependent proliferation of keratinocytes by tyrphostin tyrosine kinase blockers. J. Cell Biol. 1991, 113, 857-65.
62. Ben-Bassat H.; Vardi D. V.; Gazit A.; Klaus S. N.; Chaouat M.; Hartzstark Z.; Levitzki A. Tyrphostins suppress the growth of psoriatic keratinocytes. Exp. Dermatol. 1995, 4, 82-8.
63. Ben-Bassat H.; Levitzki A. Inhibitors of tyrosine kinases in the treatment of psoriasis. Isr. Med. Assoc. J. 2000, 2 Suppl, 69-73.
64. Powell, T. J.; Ben-Bassat, H.; Klein, B. Y.; Chen, H.; Shenoy, N.; McCollough, J.; Narog, B.; Gazit, A.; Harzstark, Z.; Chaouat, M.; Levitzki, R.; Tang, C.; McMahon, J.; Shawver, L.; Levitzki, A. Growth inhibition of psoriatic keratinocytes by quinazoline tyrosine kinase inhibitors. Br. J. Dermatol. 1999, 141, 802-10.
65. Ben-Bassat H.; Rosenbaum-Mitrani S.; Hartzstark Z.; Shlomai Z.; Kleinberger-Doron N.; Gazit A.; Plowman G.; Levitzki R.; Tsvieli R.; Levitzki A. Inhibitors of epidermal growth factor receptor kinase and of cyclin-dependent kinase 2 activation induce growth arrest, differentiation, and apoptosis of human papilloma virus 16-immortalized human keratinocytes. Cancer Res. 1997, 57, 3741-50.
66. Ben-Bassat H.; Rosenbaum-Mitrani S.; Hartzstark Z.; Levitzki R.; Chaouat M.; Shlomai Z.; Klein B. Y.; Kleinberger-Doron N.; Gazit A.; Tsvieli, R.; Levitzki A. Tyrphostins that suppress the growth of human papilloma virus 16-immortalized human keratinocytes. J. Pharmacol. Exp. Ther. 1999, 290, 1442-57.
67. Ortu, G.; Ben David, I.; Rozen, Y.; Freedman, N. M.; Chisin, R.; Levitzki, A.; Mishani, E. In vitro and in vivo investigation of an irreversible labeled EGFR inhibitor (ML03) and its potential as PET biomarker in Cancer and feasibility as an anticancer drug. Int. J. Cancer, in press.
68. Bonasera, T. A.; Ortu, G.; Rozen, Y.; Krais, R.; Freedman, N. M.; Chisin, R.; Gazit, A.; Levitzki, A.; Mishani, E. Potential (18)F-labeled biomarkers for epidermal growth factor receptor tyrosine kinase. Nucl. Med. Biol. 2001, 28, 359-74.
69. Davies, H.; Bignell, G. R.; Cox, C.; Stephens, P.; Edkins, S.; Clegg, S.; Teague, J.; Woffendin, H.; Garnett, M. J.; Bottomley, W.; Davis, N.; Dicks, E.; Ewing, R.; Floyd, Y.; Gray, K.; Hall, S.; Hawes, R.; Hughes, J.; Kosmidou, V.; Menzies, A.; Mould, C.; Parker, A.; Stevens, C.; Watt, S.; Hooper, S.; Wilson, R.; Jayatilake, H.; Gusterson, B. A.; Cooper, C.; Shipley, J.; Hargrave, D.; Pritchard-Jones, K.; Maitland, N.; Chenevix-Trench, G.; Riggins, G. J.; Bigner, D. D.; Palmieri, G.; Cossu, A.; Flanagan, A.; Nicholson, A.; Ho, J. W.; Leung, S. Y.; Yuen, S. T.; Weber, B. L.; Seigler, H. F.; Darrow, T. L.; Paterson, H.; Marais, R.; Marshall, C. J.; Wooster, R.; Stratton, M. R.; Futreal, P. A. Mutations of the BRAF gene in human cancer. Nature 2002, 417, 949-54.
70. Lyons, J. F.; Wilhelm S.; Hibner, B.; Bollag, G. Discovery of a novel Raf kinase inhibitor. Endocr. Relat. Cancer 2001, 3, 219-225.
71. Sebolt-Leopold, J. S.; Dudley, D. T.; Herrera, R.; Van Becelaere, K.; Wiland, A.; R. C., G.; Tecle, H.; Barrett, S. D.; Bridges, A.; Przybranowski, S.; Leopold, W. R.; Saltiel, A. R. Blockade of the MAP kinase pathway suppresses growth of colon tumors in vivo. Nat. Med. 1999, 5, 810-6.
72. Sausville, E. A.; Johnson, J.; Alley, M.; Zaharevitz, D.; Senderowicz, A. M. Inhibition of CDKs as a therapeutic modality. Ann. N.Y. Acad Sci. 2000, discussion, 221-2.
73. Kaubisch, A.; Schwartz, G. K. Cyclin-dependent kinase and protein kinase C inhibitors: a novel class of antineoplastic agents in clinical development. Cancer J. 2000, 6, 192-212.
74. Mani, S.; Wang, C.; Wu, K.; Francis, R.; Pestell, R. Cyclin-dependent kinase inhibitors: novel anticancer agents. Expert Opin. Investig. Drugs 2000, 9, 1849-70.
75. Murthi, K. K.; Dubay, M.; McClure, C.; Brizuela, L.; Boisclair, M. D.; Worland, P. J.; Mansuri, M. M.; Pal, K. Structure-activity relationship studies of flavopiridol analogues. Bioorg. Med. Chem. Lett. 2000, 10, 1037-41.
76. Roy, K. K.; Sausville, E. A. Early development of cyclin-dependent kinase modulators. Curr. Pharm. Des. 2001, 7, 1669-87.
77. Sausville, E. A. Complexities in the development of cyclindependent kinase inhibitor drugs. Trends Mol. Med. 2002, 8, S32-7.
78. Kelland, L. R. Flavopiridol, the first cyclin-dependent kinase inhibitor to enter the clinic: current status. Expert Opin. Investig. Drugs 2000, 9, 2903-11.
79. Senderowicz, A. M. Flavopiridol: the first cyclin-dependent kinase inhibitor in human clinical trials. Invest. New Drugs 1999, 17, 313-20.
80. Reuveni, H.; Livnah, N.; Geiger, T., Klen, S.; Ohne, O.; Cohen, I.; Benhar, M.; Gellerman, G.; Levitzki, A. Towards a PKB inhibitor: Modification of a selective PKA inhibitor by rational design. Biochemistry, in press.
81. da Rocha A. B.; Mans D. R.; Regner A.; Schwartsmann G. Targeting protein kinase C: new therapeutic opportunities against high-grade malignant gliomas? Oncologist 2002, 7, 17-33.
82. Goekjian, P. G.; Jirousek, M. R. Protein kinase C inhibitors as novel anticancer drugs. Expert Opin. Investig. Drugs 2001, 10, 2117-40.
83. Teicher, B. A.; Alvarez, E.; Menon, K.; Esterman, M. A.; Considine, E.; Shih, C.; Faul, M. M. Antiangiogenic effects of a protein kinase Cbeta-selective small molecule. Cancer Chemother. Pharmacol. 2002, 49, 69-77.
84. Ishii, H.; Jirousek, M. R.; Koya, D.; Takagi, C.; Xia, P.; Clermont, A.; Bursell, S. E.; Kern, T. S.; Ballas, L. M.; Heath, W. F.; Stramm, L. E.; Feener, E. P.; King, G. L. Amelioration of vascular dysfunctions in diabetic rats by an oral PKC beta inhibitor. Science 1996, 272, 728-31.
85. Guba, M.; von Breitenbuch, P.; Steinbauer, M.; Koehl, G.; Flegel S.; Hornung, M.; Bruns, C. J.; Zuelke, C.; Farkas, S.; Anthuber, M.; Jauch, K. W.; Geissler, E. K. Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor. Nat. Med. 2002, 8, 128-135.